Skip to main content
NCBI home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;13(2):176–184. doi: 10.1111/j.1750-3639.2003.tb00017.x

Promoter Hypermethylation of the DNA Repair Gene O 6‐Methylguanine‐DNA Methyltransferase is an Independent Predictor of Shortened Progression Free Survival in Patients with Low‐grade Diffuse Astrocytomas

Chiaki Komine 1, Takao Watanabe 1, Yoichi Katayama 1, Atsuo Yoshino 1, Takakazu Yokoyama 1, Takao Fukushima 1,✉
PMCID: PMC8095943  PMID: 12744471

Abstract

The O6‐methylguanine‐DNA methyltransferase (MGMT) plays a major role in repairing DNA damage from alkylating agents. In several human neoplasms including low‐grade diffuse astrocytomas, promoter hypermethylation of MGMT has been shown to correlate with an increased frequency of p53 mutation. In the present study, we analyzed MGMT promoter methylation by the methylation‐specific PCR in 49 newly diagnosed WHO grade II astrocytomas and evaluated its clinical usefulness. MGMT promoter methylation was found in 21 (43%) of the 49 tumors. A tight correlation existed between MGMT methylation and p53 protein accumulation (P=0.0424). The presence of MGMT methylation was significantly associated with a shorter progression free survival (PFS) on both univariate analysis (P=0.0014) and multivariate analysis (P=0.0081). It was a more powerful determinant of the PFS than age, sex, performance status, proliferative activity, or p53 expression, and was independent of the extent of surgery. In terms of the overall survival, MGMT methylation demonstrated a prognostic utility in the univariate analysis but not in the multivariate analysis. The present findings indicate that aberrant methylation of the MGMT promoter independently augurs for an unfavorable clinical course in patients with low‐grade diffuse astrocytomas. Since the presence of MGMT methylation is expected to predict an increased sensitivity to alkylating chemotherapeutic agents, earlier chemotherapy could serve to improve an unfavorable natural history in tumors with MGMT methylation.

Full Text

The Full Text of this article is available as a PDF (63.1 KB).

References

  • 1. Becker K, Gregel CM, Kaina B (1997) The DNArepair protein O6‐methylguanine‐DNA methyltransferase protects against skin tumor formation induced by antineoplastic chlorethylnitrosourea. Cancer Res 57:3335–3338. [PubMed] [Google Scholar]
  • 2. Belanich M, Pastor M, Randall T, Guerra D, Kibitel J, Alas L, Li B, Citron M, Wasserman P, White A, Eyre H, Jaeckle K, Schulman S, Rector D, Prados M, Coons S, Shapiro W, Yarosh D (1996) Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56:783–788. [PubMed] [Google Scholar]
  • 3. Bobola MS, Blank A, Berger MS, Silber JR (1995) Contribution of O6‐methylguanine‐DNA methyltransferase to monofunctional alkylating agent resistance in human brain tumor‐derived cell lines. Mol Carcinog 13:70–80. [DOI] [PubMed] [Google Scholar]
  • 4. Brüstle O, Ohgaki H, Schmitt HP, Walter GF, Ostertag H, Kleihues P (1992) Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children: association with an activated K‐ras gene. Cancer 69:2385–2392. [DOI] [PubMed] [Google Scholar]
  • 5. Chozick BS, Weiker ME, Pezzullo JC, Jackson CL, Finkelstein SD, Ambler MW, Epstein MH, Finch PW (1994) Pattern of p53 expression in human astrocytomas suggests the existence of alternate pathways of tumorigenesis. Cancer 73:406–415. [DOI] [PubMed] [Google Scholar]
  • 6. Coulondre C, Miller JH (1977) Genetic studies of the lac repressor IV: Mutagenic specificity in the lacl gene of Escherichia coli . J Mol Biol 117:577–606. [DOI] [PubMed] [Google Scholar]
  • 7. Cunningham JM, Kimmel DW, Scheithauer BW, O'Fallon JR, Novotny PJ, Jenkins RB (1997) Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: Relationships and prognostic value. J Neurosurg 86:121–130. [DOI] [PubMed] [Google Scholar]
  • 8. Esteller M, Hamilton SR, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O 6‐methylguanine‐DNAmethyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793–797. [PubMed] [Google Scholar]
  • 9. Esteller M, Toyota M, Sanchez‐Cespedes M, Capella G, Peinado MA, Watkins DN, Issa IPJ, Sidransky D, Baylin SB, Herman JG (2000) Inactivation of the DNA repair gene O 6‐methylguanine‐DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K‐ras in colorectal tumorigenesis. Cancer Res 60:2368–2371. [PubMed] [Google Scholar]
  • 10. Esteller M, Garcia‐Foncillas J, Andion E, Goodman S, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA‐repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–1354. [DOI] [PubMed] [Google Scholar]
  • 11. Esteller M, Risques R‐A, Toyota M, Capella G, Moreno V, Peinado MA, Baylin SB, Herman JG (2001) Promoter hypermethylation of the DNA repair gene O 6‐methylguanine‐DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 61:4689–4692. [PubMed] [Google Scholar]
  • 12. Fukushima T, Katayama Y, Yoshino A, Watanabe T, Kusama K, Moro I (2002) Prediction of clinical courses of diffusely infiltrating astrocytomas by telomerase expression and activity levels. Cancer Lett 187:189–196. [DOI] [PubMed] [Google Scholar]
  • 13. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB (1996) Methylation‐specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93:9821–9826. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Hilton DA, Love S, Barber R, Ellison D, Sandeman DR (1998) Accumulation of p53 and Ki‐67 expression do not predict survival in patients with fibrillary astrocytomas or the response of these tumors to radiotherapy. Neurosurgery 42:724–729. [DOI] [PubMed] [Google Scholar]
  • 15. Ishii N, Tada M, Hamou MF, Janzer RC, Meagher‐Villemure K, Wiestler OD, de Tribolet N, Van Meier EG (1999) Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor. Oncogene 18:5870–5878. [DOI] [PubMed] [Google Scholar]
  • 16. Jaeckle KA, Eyre HJ, Townsend JJ, Knudson HM, Belanich M, Yarosh DB, Bearman SI, Giroux DJ, Schold SC (1998) Correlation of tumor O6 methylguanine‐DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis‐chloroethylnitrosourea: A Southwest Oncology Group study. J Clin Oncol 16:3310–3315. [DOI] [PubMed] [Google Scholar]
  • 17. Kleihues P, Ohgaki H (1997) Genetics of glioma progression and the definition of primary and secondary glioblastoma. Brain Pathol 7:1131–1136. [Google Scholar]
  • 18. Kleihues P, Ohgaki H (1999) Primary and secondary glioblastomas: From concept to clinical diagnosis. Neuro-Oncology 1:44–51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. Kleihues P, Cavenee WK eds (2000) Pathology and Genetics of Tumours of the Nervous System. International Agency for Research on Cancer, Lyon . [Google Scholar]
  • 20. Kyritsis AP, Xu R, Bondy ML, Levin VA, Bruner JM (1996) Correlation of p53 immunoreactivity and sequencing in patients with glioma. Mol Carcinog 15:1–4. [DOI] [PubMed] [Google Scholar]
  • 21. Lim IK, Dumenco LL, Hatzoglou M, Hanson RW, Gerson SL (1990) Increased drug resistance following retroviral gene transfer of a chimeric P‐enolpyruvate carboxykinase (GTP)‐bacterial O6‐alkylguanine‐DNA alkyltrans‐ferase gene into NRK cells. Carcinogenesis 11:737–743. [DOI] [PubMed] [Google Scholar]
  • 22. Liu L, Qin X, Gerson SL (1999) Reduced lung tumorigenesis in human methylguanine DNA methyltransferase transgenic mice achieved by expression of transgene within target cell. Carcinogenesis 20:279–284. [DOI] [PubMed] [Google Scholar]
  • 23. McCormack BM, Miller DC, Budzilovich GN, Voorhees G, Ransohoff J (1992) Treatment and survival of low‐grade astrocytoma in adults –1977–1988. Neurosurgery 31:636–642. [DOI] [PubMed] [Google Scholar]
  • 24. Nakamura M, Konishi N, Tsunoda S, Nakase H, Tsuzuki T, Aoki H, Sakitani H, Inui T, Sasaki T (2000) Analysis of prognostic and survival factors related to treatment of low‐grade astrocytomas in adults. Oncology 58:108–116. [DOI] [PubMed] [Google Scholar]
  • 25. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H (2001) Promoter hypermethylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C?A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis 22:1715–1719. [DOI] [PubMed] [Google Scholar]
  • 26. Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, Kleihues P, Ohgaki H (2001) p14 ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11:159–168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Park TJ, Han S‐K, Cho Y‐K, Paik WK, Kim YB, Lim IK (2001) Methylation of O6‐methylguanine‐DNA methyltransferase gene is associated significantly with K‐ras mutation, lymph node invasion, tumor staging, and disease free survival in patients with gastric carcinoma. Cancer 92:2760–2768. [DOI] [PubMed] [Google Scholar]
  • 28. Pegg AE, Dolan ME, Moschel RC (1995) Structure, function, and inhibition of O6‐alkylguanine‐DNA‐alkyltransferase. Prog Nucleic Acid Mol Biol 51:167–223. [DOI] [PubMed] [Google Scholar]
  • 29. Philippon JH, Clemenceau SH, Fauchon FH, Foncin JF (1993) Supratentorial low‐grade astrocytomas in adults. Neurosurgery 32:554–559. [DOI] [PubMed] [Google Scholar]
  • 30. Piepmeier J, Christopher S, Spencer D, Byrne T, Kim J, Knisel JP, Lacy J, Tsukerman L, Makuch R (1996) Variations in the natural history and survival of patients with supratentorial low‐grade astrocytomas. Neurosurgery 38:872–879. [DOI] [PubMed] [Google Scholar]
  • 31. Sakumi K, Shiraishi A, Shimizu S, Tsuzuki T, Ishikawa T, Sekiguchi M (1997) Methylnitrosourea‐induced tumorigenesis in MGMT gene knockout mice. Cancer Res 57:2415–2418. [PubMed] [Google Scholar]
  • 32. Schold SC, Kokkinakis DM, Rudy JL, Moschel RC, Pegg AE (1996) Treatment of human brain tumor xenografts with O6‐benzyl‐2′ ‐deoxyguanosine and BCNU. Cancer Res 56:2076–2081. [PubMed] [Google Scholar]
  • 33. Watanabe K, Sato K, Biernat W, Tachibana O, von Ammon K, Ogata N, Yonekawa Y, Kleihues P, Ohgaki H (1997) Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res 3:523–530. [PubMed] [Google Scholar]
  • 34. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H (2001) Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60:1181–1189. [DOI] [PubMed] [Google Scholar]
  • 35. Watanabe T, Nakamura M, Kros JM, Burkhard C, Yonekawa Y, Kleihues P, Ohgaki H (2002) Phenotype versus genotype correlation in oligodendrogliomas and low‐grade diffuse astrocytomas. Acta Neuropathol 103:267–275. [DOI] [PubMed] [Google Scholar]
  • 36. Watanabe T, Huang H, Nakamura M, Wischhusen J, Weller M, Yonekawa Y, Kleihues P, Ohgaki H (2002) Aberrant methylation of the p73 gene in gliomas. Acta Neuropathol 104:357–362. [DOI] [PubMed] [Google Scholar]
  • 37. Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama Y, Fukushima T (2003) Treatment of low‐grade diffuse astrocytomas by surgery and human fibroblast interferon without radiation therapy. J Neuro-Oncol, in press. [DOI] [PubMed] [Google Scholar]
  • 38. Wolf P, Hu CH, Doffek K, Sidransky D, Ahrendt SA (2001) O6‐methylguanine‐DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non‐small cell lung cancer. Cancer Res 61:8113–8117. [PubMed] [Google Scholar]
  • 39. Zaidi NH, Pretlow TP, O'Riordan MA, Dumenco LL, Allay E, Gerson SL (1995) Transgenic expression of human MGMT protects against azoxymethane‐induced aberrant crypt foci and G to Amutations in the K‐ras oncogene of mouse colon. Carcinogenesis 16:451–456. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES